Mangoceuticals (NASDAQ:MGRX) Upgraded at Wall Street Zen

Mangoceuticals (NASDAQ:MGRX) was upgraded by analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Mangoceuticals Trading Down 6.6%

Shares of MGRX opened at $0.52 on Friday. The company’s 50-day moving average price is $0.40 and its 200 day moving average price is $0.43. Mangoceuticals has a 12-month low of $0.16 and a 12-month high of $2.75. The firm has a market cap of $8.94 million, a P/E ratio of -0.35 and a beta of 2.28.

Mangoceuticals (NASDAQ:MGRX) last announced its earnings results on Tuesday, May 19th. The company reported ($0.22) earnings per share for the quarter. Mangoceuticals had a negative return on equity of 112.00% and a negative net margin of 4,639.13%.The company had revenue of $0.07 million for the quarter.

Institutional Trading of Mangoceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of Mangoceuticals during the fourth quarter worth about $25,000. Ikarian Capital LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $102,000. Boothbay Fund Management LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $28,000. Armistice Capital LLC purchased a new stake in Mangoceuticals during the 4th quarter worth approximately $1,137,000. Finally, Jane Street Group LLC acquired a new stake in Mangoceuticals during the 4th quarter worth approximately $35,000. 56.72% of the stock is currently owned by hedge funds and other institutional investors.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.